This virtual session will focus on new research in colorectal cancer, with particular emphasis on advanced and metastatic disease. Speakers will offer updates on new data recently presented at AACR and ASCO and their impact and influence on UK practice.

By the end of the meeting delegates will understand the context and implications of these findings and how these might become relevant to their practice.

There will be an opportunity for attendees to submit questions live.


Professor John Bridgewater – University College Hospital and Chair of NCRI Upper GI Group, UK


1. Plasticity in metastasis and therapy resistance in long-term survivors


    • Dr Alison Berner – Barts Cancer Institute, UK

2. Assessment of nivolumab in patients with ring finger protein 43 (RFP43) or R-Spondin (RSPO) following standard treatment


    • Dr Ana Ortega-Franco – The Christie NHS Foundation Trust, UK

3. A biomarker enrichment trial for advanced colorectal cancer: ARIEL


    • Dr Christopher Williams University of Leeds, UK


1 category 1 (external) CPD credits for this session have been approved by the Federation of the Royal Colleges of Physicians. Delegates requiring a CPD certificate can add this during the registration process for a charge of £15. CPD Certificates will be sent automatically up to 10 days after the event date.

Who should attend?

Anyone interested or working in colorectal cancer research, diagnosis or treatment. This includes patients and carers formally involved in research, scientists, medical/clinical oncologists, GPs, surgeons, early career researchers, nurses, allied health professionals, gastroenterologists, PhD and undergraduate students, research teams and research managers/funders.


Jun 23 2022


4:00 pm - 5:00 pm



Supported by:

Amgen Oncology
Amgen Oncology